ASH 2026: What’s new in CML? Explore the program and iCMLf highlights
The 68th ASH Annual Meeting is just around the corner, once again bringing together the global hematology community in New Orleans from December 12–15, 2026.
From emerging therapies and molecular insights to persistent challenges in CML management, this year's program offers plenty of opportunities to explore the latest developments in CML research and clinical practice.
To help you make the most of ASH 2026, we've put together a selection of key CML sessions, oral presentations and posters worth adding to your schedule.
Among this year's iCMLf highlights are the annual iCMLf Forum @ASH and an oral abstract presentation by Professor Susan Branford, sharing findings from the iCMLf Genomics Alliance on the HARMONY Platform.
We look forward to seeing you at ASH 2026!
CML at ASH 2026 – Key sessions at a glance
Don’t miss these CML-focused scientific sessions:
- Education Program Session:
Persistent challenges in managing chronic myeloid leukemia
🗓️ Saturday, December 12 | 4.00 – 5.15 pm (CST) - Oral Abstract Session: Chronic myeloid leukemia: Clinical and epidemiological: biomarkers, resistance, and the molecular frontier
🗓️ Saturday, December 12 | 9.30 – 11.00 am (CST) - Oral Abstract Session: Chronic myeloid leukemia: Clinical and epidemiological: new drugs, new paradigms in CML
🗓️ Monday, December 14 | 10.30 am – 12.30 pm (CST)
Three additional CML poster presentations offer further insights into the latest research.
Download your CML schedule for ASH 2026:
View the full ASH 2026 program
Connect with the iCMLf at ASH 2026
Join us at the annual iCMLf Forum @ASH for expert discussions on new drugs, new formulations and new testing methods in CML.
- iCMLf Forum 2026: Promise to practice: New drugs, formulations and testing in CML
📅 Friday December 11| 12-2:30 pm CST
📍 SpringHill Suites New Orleans Warehouse District,
301 Saint Joseph St. | New Orleans
Register here for the 2026 iCMLf Forum
- iCMLf abstract presentation
Frontline therapy with tyrosine kinase inhibitors (TKIs) may modify the frequency of mutated ASXL1 and the cell lineage in blast phase (BP) CML:
Insights from the International CML Foundation (iCMLf) Genomics Alliance
on the HARMONY Platform
📅 Saturday, December 12 | 10.30 am | Oral Abstract Session on CML
Presenter: Professor Susan Branford
- Meet the iCMLf: Nicola Evans, Chief Executive of the iCMLf, will be at ASH and would welcome the opportunity to connect.
To arrange a meeting, please contact info@cml-foundation.org.
Catch up after ASH 2026
For those unable to attend the ASH meeting in person, join us for an ‘iCMLf Conversation’ in January to discuss CML highlights from ASH 2026.
Stay tuned for program and registration details.